Ivabradine Mercury Pharmaceuticals Limited

Ivabradine, the active ingredient in Ivabradine Mercury Pharmaceuticals Limited, is a If channel inhibitor presented as an oral dosage form for oral use. It is used to lower heart rate in patients with chronic stable angina and in heart failure with reduced ejection fraction.

GNH USA supplies Ivabradine Mercury Pharmaceuticals Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is an If channel inhibitor used in cardiovascular conditions.

- Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and lowers risk of hospitalization. - Elevated resting heart rate: helps achieve target heart‑rate control in appropriate patients.

Ivabradine may cause a range of adverse reactions, most of which are related to its heart‑rate‑lowering activity and visual pathways.

Common Side Effects: - Phosphenes (transient visual disturbances). - Bradycardia (slow heart rate). - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Severe bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Persistent visual disturbances affecting daily activities. - Severe allergic reactions (rash, swelling, anaphylaxis). - Hepatic dysfunction (elevated liver enzymes).

When prescribing ivabradine, clinicians should consider several safety measures.

- Heart‑rate monitoring: ensure resting heart rate remains above the recommended minimum. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Sick‑sinus syndrome: avoid in patients with pre‑existing sinus node dysfunction. - Concomitant bradycardic agents: adjust dose or monitor closely when used with beta‑blockers or digoxin. - Renal impairment: consider dose adjustment in severe renal dysfunction. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ivabradine interacts with several drug classes that can modify its effect on heart rate and metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction. - CYP3A4 inhibitors combined with diltiazem/verapamil: additive effect on metabolism.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine efficacy. - Antihypertensive agents: monitor blood pressure and heart rate. - Antiarrhythmic drugs (e.g., amiodarone): may require dose adjustment.